Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer

Clinical Prostate Cancer

Volumn 4, Issue 2, 2005, Pages 83-85

  Reddy, G Kesava ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BEVACIZUMAB; BORTEZOMIB; BUTYRIC ACID; DEPSIPEPTIDE; DEXAMETHASONE; DNA DEMETHYLATING AGENT; DOCETAXEL; EPOTHILONE B; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOMODULATING AGENT; ISOTRETINOIN; LBH 589; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; RETINOIC ACID; THALIDOMIDE DERIVATIVE; TRIBUTRIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ABDOMINAL PAIN; ACETYLATION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; EPIGENETICS; FATIGUE; HEART ARRHYTHMIA; HUMAN; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY CARCINOMA; MALE; NAUSEA; NONHUMAN; PANCREAS CARCINOMA; PROSTATE CANCER; SOLID TUMOR; VOMITING;

EID: 26944438280     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1540-0352(11)70115-9     Document Type: Article

References (14)

1. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97:103-115.
2. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1:194-202.
3. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45:495-528.
4. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287-99.
5. Pili R. Histone deacetylase inhibitors. Presented at die Fifth International Prostate Cancer Congress; July 1-3,2005; Rio Grande, Puerto Rico.
6. Saito A, Yamashita T., Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo and tumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96:4592-4597.
7. Sausville EA, Alley MC, Pacula-Cox CM et al: Pharmacologic evaluations of MS-275 (NSC706995), a novel benzamide structure with a unique spectrum of antitumor activity. Proc Am Assoc Cancer Res 2001; 42:927 (Abstract #4976)
8. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005; 23:3912-3922.
9. Donovan EA, Ryan Q, Acharya M, et al. Phase I pharmacokinetic- pharmacodynamic trial of weekly MS-275, an oral histone deacetylase inhibitor. J Clin Oncol 2005; 23(16 suppl):204s (Abstract #3904).
10. Gore L, Holden SN, Basche M, et al. Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 2004; 23:201 (Abstract #3026).
11. Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62:6108-6115.
12. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-3931.
13. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9:3578-3588.
14. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2004; 64:6626-6634.